 | • レポートコード：MRC2211A101 • 出版社/出版日：Transparency Market Research / 2022年9月 • レポート形態：英文、PDF、210ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界のゲムシタビンHCL市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（ブランド、ジェネリック）分析、疾患別（膵臓がん、乳がん、卵巣がん、非小細胞肺がん、その他）分析、エンドユーザー別（病院、がんセンター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、Accord Healthcare、Teva Pharmaceutical Industries Ltd.、Dr. Reddy's Laboratories Ltd.、Sun Pharmaceutical Industries Ltd.、Mylan N.V.、Fresenius SE & Co. KGaA、Pfizer, Inc.、Eli Lilly and Company、Ingenus Pharmaceuticals, LLC.、Cornerstone Pharmaceuticals, Incなどの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のゲムシタビンHCL市場規模：種類別 - ブランド製品の市場規模 - ジェネリック製品の市場規模 ・世界のゲムシタビンHCL市場規模：疾患別 - 膵臓がんにおける市場規模 - 乳がんにおける市場規模 - 卵巣がんにおける市場規模 - 非小細胞肺がんにおける市場規模 - その他疾患における市場規模 ・世界のゲムシタビンHCL市場規模：エンドユーザー別 - 病院における市場規模 - がんセンターにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界のゲムシタビンHCL市場規模：地域別 - 北米のゲムシタビンHCL市場規模 - ヨーロッパのゲムシタビンHCL市場規模 - アジア太平洋のゲムシタビンHCL市場規模 - 中南米のゲムシタビンHCL市場規模 - 中東・アフリカのゲムシタビンHCL市場規模 ・競争状況 |
Gemcitabine HCl Market – Scope of Report
TMR’s report on the global gemcitabine HCl market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global gemcitabine HCl market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gemcitabine HCl market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the gemcitabine HCl market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gemcitabine HCl market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global gemcitabine HCl market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gemcitabine HCl market.
The report delves into the competitive landscape of the global gemcitabine HCl market. Key players operating in the global gemcitabine HCl market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global gemcitabine HCl market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market gemcitabine HCl.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gemcitabine HCL Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gemcitabine HCL Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Regulatory Scenario by Region/globally
5.3. Pipeline Analysis
5.4. Key Mergers & Acquisitions
5.5. Pricing Analysis of Finished products
5.6. Overview of Manufacturers
5.7. Consumption of Gemcitabine HCl (Volume) per Region (2021)
5.8. Key Industry Developments (partnerships, mergers and acquisitions, etc.)
5.9. COVID 19 Impact Analysis
6. Global Gemcitabine HCL Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Branded
6.3.2. Generic
6.4. Market Attractiveness Analysis, by Type
7. Global Gemcitabine HCL Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Pancreatic Cancer
7.3.2. Breast Cancer
7.3.3. Ovarian Cancer
7.3.4. Non-small Cell Lung Carcinoma (NSCLC)
7.3.5. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Gemcitabine HCL Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Cancer Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Gemcitabine HCL Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Gemcitabine HCL Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Branded
10.2.2. Generic
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Pancreatic Cancer
10.3.2. Breast Cancer
10.3.3. Ovarian Cancer
10.3.4. Non-small Cell Lung Carcinoma (NSCLC)
10.3.5. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Cancer Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Gemcitabine HCL Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Branded
11.2.2. Generic
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Pancreatic Cancer
11.3.2. Breast Cancer
11.3.3. Ovarian Cancer
11.3.4. Non-small Cell Lung Carcinoma (NSCLC)
11.3.5. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Cancer Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Gemcitabine HCL Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Branded
12.2.2. Generic
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Pancreatic Cancer
12.3.2. Breast Cancer
12.3.3. Ovarian Cancer
12.3.4. Non-small Cell Lung Carcinoma (NSCLC)
12.3.5. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Cancer Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Gemcitabine HCL Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Branded
13.2.2. Generic
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Pancreatic Cancer
13.3.2. Breast Cancer
13.3.3. Ovarian Cancer
13.3.4. Non-small Cell Lung Carcinoma (NSCLC)
13.3.5. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Cancer Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Gemcitabine HCL Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Branded
14.2.2. Generic
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Pancreatic Cancer
14.3.2. Breast Cancer
14.3.3. Ovarian Cancer
14.3.4. Non-small Cell Lung Carcinoma (NSCLC)
14.3.5. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Cancer Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share/Ranking Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Accord Healthcare
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. Dr. Reddy’s Laboratories Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. Sun Pharmaceutical Industries Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Mylan N.V.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Fresenius SE & Co. KGaA
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Pfizer, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Eli Lilly and Company
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Ingenus Pharmaceuticals, LLC.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Cornerstone Pharmaceuticals, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
15.3.11. ADC Therapeutics SA
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Strategic Overview
15.3.12. Hikma Pharmaceuticals plc
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Strategic Overview
Table 01: Global Gemcitabine HCl Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Gemcitabine HCl Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 07: North America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 11: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 19: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type , 2017–2031
Table 23: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031